TMTakashi Miki

Takashi Miki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takashi Miki has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exercise-related anxiety, but not objective physical function, is associated with employment in adults with congenital heart disease

    by Momoko Ikeda, Kentaro Kamiya, Takashi Miki, Keiko Koriyama, Akiko Okada, Yumiko Hayasaka, Go Muto, Yoichiro Hirata, Toshimi Koitabashi, Junya Ako

  • Cardiac Rehabilitation and Long-Term Prognosis in Cardiovascular Disease Patients with Cancer History

    by Takashi Miki, Kentaro Kamiya, Kensuke Ueno, Nobuaki Hamazaki, Kohei Nozaki, Shota Uchida, Takumi Noda, Ken Ogura, Kazuki Hotta, Emi Maekawa, et al.

    Background: Cancer and cardiovascular disease (CVD) share common risk factors, and the development of CVD in cancer survivors is a significant event that worsens prognosis. Comprehensive cardiac rehabilitation (CR) has been reported to be associated with improved prognosis, including risk of death and rehospitalisation, in patients with CVD. However, the benefits of CR to patients with both cancer and CVD is unclear. Aims: This study aimed to investigate the usefulness of CR in CVD patients with cancer history. Methods: We retrospectively reviewed 1,424 CVD patients with a cancer history (median age: 76 [69–81] years). Primary and secondary outcomes were all-cause mortality and composite events of all-cause death and CVD-related rehospitalisation, respectively. CR participation was defined as attending rehabilitation at least once within three months of discharge. We performed propensity score (PS) matching for CR, followed by Cox regression analysis, to assess the association between CR and prognosis. Results: During the median follow-up period of 1.8 (0.7–3.4) years, 286 deaths and 465 composite events occurred. After PS matching, 1,008 patients (504 pairs) were included, with standardised mean differences of < 0.1 for all covariates. CR participation was associated with a significantly lower risk of all-cause mortality (Hazard ratio [HR]: 0.54, 95% confidence interval [CI]: 0.41–0.73, P < 0.001) and composite event rates (HR: 0.62, 95% CI: 0.50–0.78, P < 0.001) compared to CR non-participation. Conclusion: CR participation was associated with a lower risk of poor prognostic events in CVD patients with a history of cancer.


  • Ability of the FRAIL scale questionnaire to screen physical frailty and its prognostic value in older patients with cardiovascular disease and cognitive decline

    by Takumi Noda, Tomohiko Ozeki, Kentaro Kamiya, Nobuaki Hamazaki, Kohei Nozaki, Shota Uchida, Kensuke Ueno, Ken Ogura, Takashi Miki, Emi Maekawa, et al.

    Aims: The FRAIL scale questionnaire is a brief measure of physical frailty in patients with cardiovascular disease (CVD); however, its performance in those with concomitant cognitive impairment remains uncertain. We investigated the accuracy of the FRAIL scale in identifying physical frailty defined by the Fried criteria and its association with adverse events in older patients with CVD and cognitive decline. Methods and results: This retrospective cohort study comprised 318 patients (male, 66.7%; median age, 79 years) with CVD (≥60 years old) who had cognitive impairment (Mini-Cog <3 points) and completed the FRAIL scale. The accuracy of the FRAIL scale for identifying physical frailty was evaluated using the area under the curve (AUC). Associations with frailty, motor functions (e.g. leg strength, walking speed, 6-min walk test distance), and prognosis was tested using multivariable regression models and survival analysis. The AUC for predicting physical frailty was 0.749 (95% confidence interval [CI], 0.697–0.801). Higher FRAIL scale scores were associated with physical frailty (adjusted odds ratio, 2.087; 95% CI, 1.647–2.645) and motor function decline (all P < 0.05). During follow-up (median, 335 days), 70 patients experienced the first composite event (all-cause death or cardiovascular rehospitalization). Frailty assessed by the FRAIL scale was associated with higher composite event rates (adjusted hazard ratio, 1.918; 95% CI, 1.134–3.243). Conclusion: In older patients with CVD and cognitive decline, higher FRAIL scale scores are associated with objectively assessed physical frailty and worse prognosis. These findings indicate that the FRAIL scale questionnaire is applicable for frailty screening and risk stratification in this population.


  • Screening for sarcopenia with SARC-F in older patients hospitalized with cardiovascular disease

    by Takumi Noda, Kentaro Kamiya, Nobuaki Hamazaki, Masashi Yamashita, Takashi Miki, Kohei Nozaki, Shota Uchida, Kensuke Ueno, Emi Maekawa, Tasuku Terada, et al.

    Aims: SARC-F ≥ 4 points are used for detecting sarcopenia; however, finding a lower SARC-F cut-off value may lead to early detection of sarcopenia. We investigated the SARC-F score with the highest sensitivity and specificity values to identify sarcopenia in older patients with cardiovascular disease (CVD). Motor performances were also examined for each SARC-F score. Methods and results: This retrospective cross-sectional study examined the sensitivity and specificity of every 1-point increase in the SARC-F score to predict sarcopenia. Eligible participants included patients with CVD (≥65 years old) who were admitted for acute CVD treatment and participated in cardiac rehabilitation. Patients completed the SARC-F questionnaire and the sarcopenia assessment. Area under the curves (AUCs) were investigated for the ability to predict sarcopenia. Multivariable linear regression was used to compare the mean value of physical functions (e.g. walking speed, leg strength, and 6 min walking distance) of each SARC-F score. A total of 1066 participants (63.8% male; median age: 76 years) were included. Sarcopenia was present in 401 patients. A SARC-F cut-off ≥2 presented the optimal balance between sensitivity (68.3%) and specificity (55.6%) to detect sarcopenia (AUCs = 0.658; 95% confidence interval: 0.625–0.691). When the patients had low scores (1–3), every 1 point increase in the SARC-F score was associated with lower physical functions such as lower muscle strength and shorter walking distance (all P < 0.001). Conclusion: A SARC-F cut-off ≥2 was optimal for screening sarcopenia, and even a low SARC-F score is useful in detecting sarcopenia and low physical function at an early stage in patients with CVD.


  • Current status of flow-mediated vasodilation and nitroglycerin-mediated vasodilation

    by Takashi Miki

    血流依存性血管拡張反応(%FMD)は,血管内皮障害や動脈硬化の進展状態を把握するための重要な検査である.さらに,ニトログリセリン誘発性内皮非依存性血管拡張反応(%NMD)は,血管平滑筋自体の機能を評価するために推奨されている.現在,%FMDと%NMDの評価の組み合わせは,血管機能障害が血管内皮機能障害のみによって引き起こされているのか,血管平滑筋機能障害まで進展しているのかを判断する重要な検査であり,多くの施設で臨床応用されている.超音波診断装置を用いて算出された%FMDおよび%NMDは,安静時の血管直径から最大拡張時の血管直径の変化率として算出される.それらを用いた先行研究では,%FMDと%NMDが心血管イベントの予測因子になり得ることが示唆され,%FMDは,冠状動脈疾患,心筋梗塞,慢性心不全,高血圧,および頸動脈硬化症の内皮機能障害における心血管イベントの予測因子となることが多数報告されている.